Want to see TSE:HBP full AI Analyst Report?
HBP Stock Chart & Stats
C$1.99
-C$0.01(-0.70%)
At close: 4:00 PM EDT
C$1.99
-C$0.01(-0.70%)
Day’s Range― - ―
52-Week RangeC$1.10 - C$5.40
Previous CloseN/A
Volume206.00
Average Volume (3M)2.73K
Market Cap
C$89.36M
Enterprise ValueC$111.32M
Total Cash (Recent Filing)C$2.84M
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding76,378,100
10 Day Avg. Volume2,843
30 Day Avg. Volume2,726
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved EquityVery low debt relative to equity reduces solvency pressure, while the shift from negative to positive equity improves financial stability. This provides a stronger balance-sheet base for funding clinical development than in earlier periods.
Experienced Clinical LeadershipAdding experienced oncology leadership may strengthen trial design, regulatory preparation and execution as multiple assets advance. Better clinical oversight could improve development efficiency, although the programs remain unproven and require successful trials.
Multi-asset Oncology PipelineSeveral oncology candidates provide more than one potential path to clinical value and future partnering or commercialization. Portfolio breadth can reduce reliance on a single asset, while upcoming milestones create opportunities for fundamental progress.
Bears Say
No Recurring RevenueWithout product or licensing revenue, Helix lacks an operating base to absorb fixed costs and support development internally. Persistent losses leave future value dependent on clinical progress and eventual monetization of drug candidates.
Ongoing Cash BurnNegative operating and free cash flow means the business is not self-funding its research programs. Continued cash consumption can require additional capital, potentially limiting development pace or diluting existing shareholders over the medium term.
Clinical And Regulatory Execution RiskClinical-stage assets face substantial trial, regulatory and efficacy uncertainty before they can generate revenue. Delays, unsuccessful studies or safety issues could materially reduce pipeline value because the company has no established commercial product base.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$1.10 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$89.36M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Nov 04, 2026 which is in 40 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Jun 10, 2026. The company reported -C$0.009 earnings per share for the quarter.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report. Following the earnings report the stock price went up 3.947%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―